Aspira Women's Health Inc. (AWH)
Chart Events
Performance Outlook
| Previous Close | 0.5700 |
| Open | 0.5650 |
| Bid | 0.5860 x 800 |
| Ask | 0.5869 x 900 |
| Day's Range | 0.5650 - 0.6000 |
| 52 Week Range | 0.2800 - 1.2900 |
| Volume | |
| Avg. Volume | 273,475 |
| Market Cap | 73.075M |
| Beta (5Y Monthly) | 2.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3120 |
| Earnings Date | Mar 21, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AWH
Related Research
- Aspira Women's Health Inc.Analyst Report: Abbott LaboratoriesAbbott Laboratories is a diversified healthcare company that develops, manufactures and markets a wide range of medical products and services. Its main product lines are nutritionals for adults and infants, diagnostic systems, vascular implants, cardiac rhythm management products, and diabetes care products.RatingFair ValueEconomic Moat6 days agoArgus Research
- GlobeNewswire
Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights
Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results consistent with previously provided cash utilization guidance for the fourth quarter and full year of 2022 Further reduced staff to achieve anticipated year-over-year salary cost savings of about $6 million in 2023 AUSTIN, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company
- GlobeNewswire
Aspira Women’s Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses
Provides clinical validation for the use of OvaWatchSM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses Paper published in the peer-reviewed journal, Frontiers in Medicine AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced its manuscript, entitled: “Validation of deep neural network-based algorithm supporting clinical mana
- GlobeNewswire
Aspira Women’s Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio
Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatchSM, through the 2023 Omnibus Spending Bill Granted a new PLA Code for OvaWatch by the American Medical Association Expanded Medicaid coverage adding another 5 states: Virginia, Alabama, Maine, Pennsylvania, and Rhode Island AUSTIN, Texas, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the
